Polycythemia Vera: A Malignancy in Hematology: Review Article
##plugins.themes.academic_pro.article.sidebar##
Published
Aug 31, 2023
Download
Statistic
Abstract views: 19 , Pdf downloads: 9
##plugins.themes.academic_pro.article.main##
Abstract
ABSTRACT: Myeloid neoplasm is a condition in which myeloid cells can undergo excessive clonal proliferation. One classification of the disease is polycythemia vera.Polycythemia Vera (PV) is a condition where there is an increase in the number of red blood cells reaching 125% of the calculation based on body mass and sex. PV is caused by mutations in the JAK2 gene. PV disease diagnosisBased on the results of the history, physical examination and supporting examinations in the form of laboratory tests. PV disease can be managed with phlebotomy, administration of aspirin, and cytoreductive drugs. Patients with PV can survive more than 10 years if treated quickly and appropriately.
##plugins.themes.academic_pro.article.details##
References
1. Adiwijono et al. BUKU AJAR ILMU PENYAKIT DALAM. IV. Jakarta; 2014.
2. Cahyanur R, Rinaldi I. Pendekatan Klinis Polisitemia. 2019;6(3):156–61.
3. S S, I A, AW S, B S, AF S. Buku Ajar Ilmu Penyakit Dalam Jilid I FK UI Jakarta: Interna Publishing; 2014.
4. Hoffbrand AV, Moss PAH. Kapita Selekta Hematologi Edisi 7 Jakarta: EGC; 2018
5. Cahyanur R, Rinaldi I. Pendekatan Klinis Polisitemia. Jurnal Penyakit Dalam Indonesia. 2019 September; 6
6. Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: Insights into pathophysiology and treatments in 2017. Molecular Med. 2018;24(1):11
7. Maffioli M, Mora B, Passamonti F. Polycythemia vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches. Clinical Advances in Hematology & Oncology. 2017;15(9):700-7
8. Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Journal of Translational Medicine. 2018;16:360
9. Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97:183-97
10. U.S National Library of Medicine. Genetics Home Reference [Internet]. 2019 [cited 2019 March 27. Available from: https://ghr.nlm.nih.gov/gene/JAK2
11. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8:3
12. Helbig G. Classical Philadelphia-negative myeloproliferative neoplasms: Focus on mutations and JAK2 inhibitors. Medical Oncology. 2018;35(9):119
13. de Freitas RM, Maranduba CMdC. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Revista Brasileira de Hematologia e Hemoterapia. 2015;37(5):348-53.
14. McMullin MF, Wilkins BS, Harrison CN. Management of polycythemia vera: A critical review of current data. British Journal of Hematology. 2015;172(3):337-49
15. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008; 111(7):3383-7
16. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiologi and consequences. Springer Nature. 2018 may.
17. Liesveld J. Polycythemia Vera. Primary Polyvythemia. 2019 February
2. Cahyanur R, Rinaldi I. Pendekatan Klinis Polisitemia. 2019;6(3):156–61.
3. S S, I A, AW S, B S, AF S. Buku Ajar Ilmu Penyakit Dalam Jilid I FK UI Jakarta: Interna Publishing; 2014.
4. Hoffbrand AV, Moss PAH. Kapita Selekta Hematologi Edisi 7 Jakarta: EGC; 2018
5. Cahyanur R, Rinaldi I. Pendekatan Klinis Polisitemia. Jurnal Penyakit Dalam Indonesia. 2019 September; 6
6. Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: Insights into pathophysiology and treatments in 2017. Molecular Med. 2018;24(1):11
7. Maffioli M, Mora B, Passamonti F. Polycythemia vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches. Clinical Advances in Hematology & Oncology. 2017;15(9):700-7
8. Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Journal of Translational Medicine. 2018;16:360
9. Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97:183-97
10. U.S National Library of Medicine. Genetics Home Reference [Internet]. 2019 [cited 2019 March 27. Available from: https://ghr.nlm.nih.gov/gene/JAK2
11. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8:3
12. Helbig G. Classical Philadelphia-negative myeloproliferative neoplasms: Focus on mutations and JAK2 inhibitors. Medical Oncology. 2018;35(9):119
13. de Freitas RM, Maranduba CMdC. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Revista Brasileira de Hematologia e Hemoterapia. 2015;37(5):348-53.
14. McMullin MF, Wilkins BS, Harrison CN. Management of polycythemia vera: A critical review of current data. British Journal of Hematology. 2015;172(3):337-49
15. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008; 111(7):3383-7
16. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiologi and consequences. Springer Nature. 2018 may.
17. Liesveld J. Polycythemia Vera. Primary Polyvythemia. 2019 February